Crossject
Company profile
Primary focus
Development of a needle-free, pre-filled, single-use auto-injector platform for rapid administration of emergency medications.
Why it’s included
The company develops and manufactures the ZENEO Midazolam needle-free autoinjector, explicitly funded by BARDA and Project BioShield for nerve agent exposure, meeting the topic's requirements for rapid-onset, field-deployable chemical threat countermeasures.
Relevant capabilities
- Needle-free pre-filled single-use auto-injector design and development
- Clinical development for emergency indications
- Manufacturing and scale-up of pre-filled auto-injector devices
- Human factors engineering for emergency-use devices
- Regulatory strategy and support for FDA authorization
Commercial sectorAutoinjectors and Rapid Drug Delivery Devices
Technology classesBenzodiazepine anticonvulsants for nerve-agent seizures, Autoinjector drug delivery devices
Relevant commercial products
- Needle-free, pre-filled, single-use auto-injector platform
- ZENEO
- ZEPIZURE®
Relevant patents
5 families, 5 publications- Needleless injection device equipped with a protected reservoir US-8784371-B2
- Needleless injection device with an angularly-positionable closure stopper US-10799638-B2
- Needleless injection device with a curved membrane US-11738151-B2
- Needleless injection device with an improved sealing gasket US-10675409-B2
- Needleless injection device with sliding membrane US-10653839-B2